Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

Am J Health Syst Pharm. 2007;64(12):1265-1273.

Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.